Filing Details

Accession Number:
0001487371-20-000066
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-02-27 20:59:34
Reporting Period:
2020-02-25
Accepted Time:
2020-02-27 20:59:34
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1487371 Genmark Diagnostics Inc. GNMK Surgical & Medical Instruments & Apparatus (3841) 272053069
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1543884 Michael Gleeson 5964 La Place Court
Carlsbad CA 92008
Svp, Corp. Accounts No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-02-25 43,125 $0.00 369,416 No 4 A Direct
Common Stock Acquisiton 2020-02-25 43,125 $0.00 412,541 No 4 A Direct
Common Stock Disposition 2020-02-25 1,053 $3.81 411,488 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 A Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Market Stock Units Acquisiton 2020-02-25 28,750 $0.00 28,750 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
28,750 No 4 A Direct
Footnotes
  1. The amount reported reflects restricted stock units granted to the Reporting Person pursuant to the Issuer's 2010 Equity Incentive Plan. The restricted stock units vest 25% on February 25, 2021 and the remaining shares subject to such award vest in 12 equal quarterly installments thereafter.
  2. The amount reported reflects restricted stock units granted to the Reporting Person pursuant to the Issuer's 2010 Equity Incentive Plan. The restricted stock units vest 50% on February 25, 2021 and the remaining shares subject to such award vest in 4 equal quarterly installments thereafter.
  3. The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units.
  4. Each market stock unit ("MSU") represents the contingent right to receive, following vesting, between 0% and 200% of one share of the Issuer's common stock, subject to the level of achievement of applicable performance conditions. The resulting number of shares acquired upon vesting of the MSUs, if any, is based on the Issuer's total shareholder return for each performance period as compared to the NASDAQ Composite Index.
  5. The MSUs vest in three equal installments, on each of December 31, 2020, December 31, 2021, and December 31, 2022; provided that, at the end of the second and third performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the NASDAQ Composite Index.